Price Don’t Lie: After Making 52-Week Low, Is Cellectis SA (ADR)’s Near-Term Analysis Negative?

Price Don't Lie: After Making 52 Week Low, Is Cellectis SA (ADR)'s Near Term Analysis Negative?

The stock of Cellectis SA (ADR) (NASDAQ:CLLS) hit a new 52-week low and has $16.13 target or 9.00% below today’s $17.72 share price. The 7 months bearish chart indicates high risk for the $623.42 million company. The 1-year low was reported on Oct, 31 by Barchart.com. If the $16.13 price target is reached, the company will be worth $56.11 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 20,301 shares traded hands. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 34.22% since March 29, 2016 and is downtrending. It has underperformed by 37.70% the S&P500.

According to Zacks Investment Research, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.”

More important recent Cellectis SA (ADR) (NASDAQ:CLLS) news were published by: Quotes.Wsj.com which released: “DOW JONES, A NEWS CORP COMPANY” on March 21, 2015, also Marketwatch.com published article titled: “/quotes/zigman/3870025/realtime”, Schaeffersresearch.com published: “Cellectis SA (CLLS) Defies Sector Headwinds on Cancer Breakthrough” on May 06, 2016. More interesting news about Cellectis SA (ADR) (NASDAQ:CLLS) was released by: Bidnessetc.com and their article: “Pfizer Inc. Interested In Acquiring French Biotech Firm Cellectis SA (ADR …” with publication date: June 01, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment